Updates & Developments

Access to Treatment in Québec – Have Your Say

L’INESSS in Québec is evaluating inotersen (Tegsedi – Akcea Therapeutics Canada) a treatment for adults with hATTR amyloidosis polyneuropathy. L’INESSS does this evaluation to determine whether to recommend the drug for reimbursement by the Québec government....

read more

HAC Needs YOU! Tegsedi Survey Closes March 1

If you are a person living with hATTR amyloidosis, or a caregiver for a person living with hATTR amyloidosis, we would greatly appreciate it if you could take 15 minutes to complete a questionnaire regarding Tegsedi, a medication recently approved by Health Canada....

read more

Report on hATTR treatments shared at ICER meeting

A report on treatments for hereditary transthyretin-related (hATTR) amyloidosis by the  Institute for Clinical and Economic Review (ICER) was reviewed by the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) at the ICER meeting held in Chicago...

read more

Sign up to Stay in Touch!

Get important updates, including Canadian-focused news and information about hATTR amyloidosis, delivered to your inbox.

12 + 4 =

*By submitting this form, you are consenting to receive emails from Hereditary Amyloidosis Canada. You can revoke your consent to receive emails at any time by using the unsubscribe link, found at the bottom of every email.

Share This